Related Experiment Video
Updated: Jun 21, 2026

Morphometric Analyses of Retinal Sections
Published on: February 19, 2012
Effects of Cyclooxygenase Inhibitors on Apoptotic Neuroretinal Cells
Anja-Kristina Brust1, Holger K Ulbrich, Gail M Seigel
1Department of Ophthalmology, Johannes Gutenberg University of Mainz, Germany.
Abstract:
Glaucoma is characterized by a loss of retinal ganglion cells (RGC) which is associated with a decrease of visual function. Neuroprotective agents as a new therapeutic strategy could prevent the remaining neurons from apoptotic cell death. Previous studies have shown the involvement of the Cyclooxygenase (COX)-2 signalling in the apoptotic death of neurons. Herein we investigated the neuroprotective effect of COX-1/COX-2- and selective COX-2- inhibitors on apoptotic. R28, a neuroretinal cell line and determined the PGE(2) levels by ELISA. Furthermore we investigated differences in protein expression in the cells after exposure to elevated pressure compared to untreated cells by ProteinChip analysis.In addition, a protein profiling study of the cells after exposure to elevated pressure was performed. The protein expression profiles were measured by SELDI-TOF (Surface Enhanced Laser Desorption/Ionization-time of flight) Protein Chips. The protein identification was performed by mass spectrometry (MS).It could be shown that COX-2 inhibition significantly prevented the cells from apoptosis and reduced the PGE(2) concentrations. Selective COX-2 inhibitors were significant more potent than non-selective inhibitors or COX-1 inhibitors. We found differently expressed protein patterns in neuroretinal cells cultured at atmospheric pressure compared to those cells exposed to elevated pressure with or without celecoxib respectively. We identified three biomarkers, ubiquitin, HSP10 and NDKB, which were differently expressed in the groups. However, our data indicates a distinct neuroprotective effect of COX-2 inhibition. The local treatment with selective COX-2 inhibitors might provide an innovative strategy of therapeutic intervention for glaucoma.
Insights
Cyclooxygenase (COX)-2 inhibitors protect retinal cells from apoptosis, a key factor in glaucoma. Selective COX-2 inhibitors show significant neuroprotective effects, suggesting a novel therapeutic strategy for glaucoma.
Area of Science:
- Ophthalmology
- Neuroscience
- Pharmacology
Background:
- Glaucoma involves retinal ganglion cell (RGC) loss, leading to vision impairment.
- Neuroprotection offers a strategy to prevent RGC apoptosis.
- Cyclooxygenase (COX)-2 signaling is implicated in neuronal apoptotic death.
Purpose of the Study:
- To investigate the neuroprotective effects of COX-1/COX-2 inhibitors on RGCs.
- To assess the impact of these inhibitors on prostaglandin E2 (PGE2) levels.
- To identify protein expression changes in RGCs under elevated pressure with and without COX-2 inhibition.
Main Methods:
- Utilized the R28 neuroretinal cell line.
- Measured PGE2 concentrations using ELISA.
- Analyzed protein expression profiles via SELDI-TOF MS and ProteinChip analysis.
Main Results:
- COX-2 inhibition significantly reduced RGC apoptosis and PGE2 levels.
- Selective COX-2 inhibitors were more potent than non-selective or COX-1 inhibitors.
- Identified differential expression of ubiquitin, HSP10, and NDKB biomarkers under elevated pressure.
Conclusions:
- COX-2 inhibition demonstrates a clear neuroprotective effect in RGCs.
- Selective COX-2 inhibitors present a promising therapeutic avenue for glaucoma.
- Targeted local treatment with selective COX-2 inhibitors could be an innovative glaucoma intervention.
